Foghorn Therapeutics (FHTX) Expected to Release Quarterly Earnings on Tuesday

Foghorn Therapeutics (NASDAQ:FHTX) is expected to be issuing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Foghorn Therapeutics to post earnings of ($0.23) per share and revenue of $7.0490 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Foghorn Therapeutics (NASDAQ:FHTX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). The company had revenue of $3.27 million during the quarter, compared to analysts’ expectations of $7.94 million. On average, analysts expect Foghorn Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foghorn Therapeutics Stock Down 1.8%

FHTX stock traded down $0.10 during trading on Tuesday, hitting $5.11. The company had a trading volume of 4,438 shares, compared to its average volume of 198,216. The firm has a 50-day moving average price of $4.57 and a 200-day moving average price of $5.02. The firm has a market cap of $299.73 million, a PE ratio of -4.38 and a beta of 2.86. Foghorn Therapeutics has a 1-year low of $3.27 and a 1-year high of $6.95.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on FHTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Foghorn Therapeutics in a research note on Friday, July 17th. Wall Street Zen cut Foghorn Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Foghorn Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $11.43.

Institutional Trading of Foghorn Therapeutics

A number of institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. boosted its holdings in Foghorn Therapeutics by 13,755.0% during the third quarter. Russell Investments Group Ltd. now owns 5,542 shares of the company’s stock worth $27,000 after buying an additional 5,502 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Foghorn Therapeutics by 48.0% in the third quarter. BNP Paribas Financial Markets now owns 7,103 shares of the company’s stock valued at $35,000 after buying an additional 2,305 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Foghorn Therapeutics by 136.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,213 shares of the company’s stock valued at $43,000 after acquiring an additional 5,323 shares during the period. Occudo Quantitative Strategies LP acquired a new stake in shares of Foghorn Therapeutics during the 3rd quarter valued at approximately $58,000. Finally, Invesco Ltd. acquired a new stake in shares of Foghorn Therapeutics during the 4th quarter valued at approximately $58,000. 61.55% of the stock is currently owned by hedge funds and other institutional investors.

About Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.